[Antihypertensive effect of a new form of XXXX compared to a beta-blocker during chronic administration].

@entity1 @entity101 @entity10719 @entity594 @entity13520
The aim of this study was to test the efficacy of a 20 mg tablet preparation of @entity594 alone in twice daily dosage, in the treatment of moderate @entity101 (95 greater than or equal to @entity13520 less than or equal to 115 mmHg). Efficacy was defined as the ability to maintain treatment for 6 months with a fall in @entity13520 of a least 5 mmHg after the first month, and with a @entity13520 100 mmHg from the second month. One hundred and seventy seven @entity1 were recruited from november 1981 to december 1982, 55% during the first three months of the trial. There were 95 @entity1 (54%) and 82 @entity1 , with a mean age of 55.6 +/- 10 years. The @entity13520 ranged from 96 to 111 mmHg in 80% of cases. The @entity1 were randomly allocated in lots of 6, to three groups: placebo (58 @entity1 ), @entity594 (57 @entity1 ) and @entity10719 (61 @entity1 ). The comparability of 21 parameters amongst these 3 groups was verified. After 1 month of placebo, 25 @entity1 did not meet the criteria of inclusion and were excluded from the study. During this phase, 19 @entity1 (10.5%) complained of at least one side effect. Of the 152 @entity1 who received active treatment, 34 (22.4%) were "wrongly included", 17 did not complete the test period for undefined reasons and were considered to have been "lost to follow-up", and 6 @entity1 "deviated" from the protocol. These 3 groups were taken into account in the statistical analysis of the graphs of non-failure.
